Benzodiazepines vs phenobarbital (as active placebo)
Acceptability · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
- no estimate extracted1 study · 21 participantsVery low
Findings
What do systematic reviews say?
125 questions · 125 findings · 7 reviews
No studies found 44 · 35.2%GRADE not reported 1 · 0.8%Very low 52 · 41.6%Low 21 · 16.8%Moderate 7 · 5.6%High 0 · 0%
Benzodiazepines vs phenobarbital (as active placebo)
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not measured · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Benzodiazepines vs phenobarbital (as active placebo)
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether benzodiazepines changes tardive dyskinesia: no clinically important improvement compared with phenobarbital (as active placebo) (very low certainty).
1 finding from 1 review
- RR 0.44 [0.2, 0.96]1 study · 21 participantsVery low
Benzodiazepines vs phenobarbital (as active placebo)
Tardive dyskinesia: deterioration in symptoms ‐ not measured · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Benzodiazepines vs phenobarbital (as active placebo)
Adverse events: any · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether benzodiazepines changes adverse events: any compared with phenobarbital (as active placebo) (very low certainty).
1 finding from 1 review
- RR 1.53 [0.97, 2.41]1 study · 21 participantsVery low